医学
非酒精性脂肪肝
疾病
脂肪肝
重症监护医学
电流(流体)
肝病
生物信息学
内科学
电气工程
生物
工程类
作者
Idoia Genua,Kenneth Cusi
出处
期刊:Diabetes Spectrum
[American Diabetes Association]
日期:2024-02-01
卷期号:37 (1): 48-58
被引量:1
摘要
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI